Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent inactivated enterovirus vaccine (Vero cell)
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Quadrivalent inactivated enterovirus vaccine (Vero cell)**, also called **HFMD4**, is a SINOVAC-developed prophylactic vaccine candidate intended to prevent hand, foot, and mouth disease and related enterovirus illnesses caused by enterovirus 71, coxsackievirus A16, coxsackievirus A10, and coxsackievirus A6. It contains inactivated antigens produced using Vero cells and is designed to elicit serotype-specific neutralizing antibody responses against all four targeted enteroviruses. The candidate entered a multicenter, randomized, double-blind, placebo-controlled Phase IIIa study in children aged 6–71 months in China after Phase I/II studies reported acceptable tolerability, safety, and immunogenicity following a two-dose schedule.
- Other names
- inactivated quadrivalent enterovirus vaccine (Vero cell)四价肠道病毒灭活疫苗（Vero细胞）tetravalent inactivated enterovirus vaccine (Vero cell)
02
Targets
CA16 (Coxsackievirus A16)CVA6 (Coxsackievirus A6)CV-A10 (Coxsackievirus A10)
Beyond the preview
Go deeper on quadrivalent inactivated enterovirus vaccine (Vero cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent inactivated enterovirus vaccine (Vero cell).